{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:41:39Z","timestamp":1788194499909,"version":"build-2803163510"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The management of multidrug-resistant tuberculosis (MDR-TB) remains challenging. Treatment outcome is influenced by multiple factors; the specific roles of diabetes and glycemic control remain uncertain. This study aims to assess the impact of glycemic control on drug exposure, to investigate the association between drug exposure and treatment outcomes, and to identify clinically significant thresholds predictive of treatment outcome, among patients with diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter prospective cohort study involved patients with confirmed MDR-TB and diabetes. Drug exposure level was estimated by noncompartmental analysis. The minimum inhibitory concentrations (MICs) were determined for the individual Mycobacterium tuberculosis isolates. The influence of poor glycemic control (glycated hemoglobin \u22657%) on drug exposure and the associations between drug exposure and treatment outcome were evaluated by univariate and multivariate analysis. Classification and regression tree analysis was used to identify the drug exposure\/susceptibility thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 131 diabetic participants, 43 (32.8%) exhibited poor glycemic control. Poor glycemic control was independently associated with decreased exposure to moxifloxacin, linezolid, bedaquiline, and cycloserine, but not clofazimine. Additionally, a higher ratio of drug exposure to susceptibility was found to be associated with a favorable MDR-TB treatment outcome. Thresholds predictive of 6-month culture conversion and favorable outcome were bedaquiline area under the concentration\u2013time curve (AUC)\/MIC \u2265245 and moxifloxacin AUC\/MIC \u226567, demonstrating predictive accuracy in patients, regardless of their glycemic control status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Glycemic control and optimal TB drug exposure are associated with improved treatment outcomes. This dual management strategy should be further validated in randomized controlled trials of patients with MDR-TB and diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae329","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T10:48:37Z","timestamp":1718794117000},"page":"524-533","source":"Crossref","is-referenced-by-count":12,"title":["Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From China"],"prefix":"10.1093","volume":"79","author":[{"given":"Yue","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Davies","family":"Forsman","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital , Stockholm , Sweden"},{"name":"Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sainan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bruchfeld","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital , Stockholm , Sweden"},{"name":"Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, School of Pharmacy , University of Sydney, Sydney , Australia"},{"name":"Department of Clinical Pharmacology, Westmead Hospital , Sydney , Australia"},{"name":"Sydney Institute for Infectious Diseases, University of Sydney , Sydney , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"2024081609320830000_ciae329-B1","author":"World Health Organization"},{"key":"2024081609320830000_ciae329-B2","doi-asserted-by":"crossref","first-page":"190035","DOI":"10.1183\/16000617.0035-2019","article-title":"Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives","volume":"28","author":"Pontali","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2024081609320830000_ciae329-B3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5588\/ijtld.22.0619","article-title":"Diabetes mellitus and TB\u2014finding strategies to reduce the double burden of disease","volume":"27","author":"Forsman","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024081609320830000_ciae329-B4","doi-asserted-by":"crossref","first-page":"e3066","DOI":"10.1002\/dmrr.3066","article-title":"Coprevalence of type 2 diabetes mellitus and tuberculosis in low-income and middle-income countries: a systematic review","volume":"35","author":"McMurry","year":"2019","journal-title":"Diabetes\/Metab Res Rev"},{"key":"2024081609320830000_ciae329-B5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1159\/000348374","article-title":"Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis","volume":"86","author":"Kang","year":"2013","journal-title":"Respiration"},{"key":"2024081609320830000_ciae329-B6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jfma.2015.10.002","article-title":"Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt","volume":"115","author":"Gadallah","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"2024081609320830000_ciae329-B7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3892\/etm.2015.2966","article-title":"Efficacy and effect of free treatment on multidrug-resistant tuberculosis","volume":"11","author":"Zhang","year":"2016","journal-title":"Exp Ther Med"},{"key":"2024081609320830000_ciae329-B8","doi-asserted-by":"crossref","first-page":"e1402","DOI":"10.1016\/S2214-109X(23)00324-8","article-title":"Nutritional support for adult patients with microbiologically confirmed pulmonary tuberculosis: outcomes in a programmatic cohort nested within the RATIONS trial in Jharkhand, India","volume":"11","author":"Bhargava","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2024081609320830000_ciae329-B9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.202007-2634OC","article-title":"Glycemic trajectories and treatment outcomes of patients with newly diagnosed tuberculosis: a prospective study in eastern China","volume":"204","author":"Liu","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024081609320830000_ciae329-B10","doi-asserted-by":"crossref","first-page":"e0121698","DOI":"10.1371\/journal.pone.0121698","article-title":"The influence of diabetes, glycemic control, and diabetes-related comorbidities on pulmonary tuberculosis","volume":"10","author":"Chiang","year":"2015","journal-title":"PLoS One"},{"key":"2024081609320830000_ciae329-B11","first-page":"144","article-title":"Effect of poor glycemic control in newly diagnosed patients with smear-positive pulmonary tuberculosis and type-2 diabetes mellitus","volume":"42","author":"Mahishale","year":"2017","journal-title":"Iranian J Med Sci"},{"key":"2024081609320830000_ciae329-B12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/thoraxjnl-2015-207686","article-title":"The effect of diabetes control status on treatment response in pulmonary tuberculosis: a prospective study","volume":"72","author":"Yoon","year":"2017","journal-title":"Thorax"},{"key":"2024081609320830000_ciae329-B13","doi-asserted-by":"crossref","first-page":"e01383-18","DOI":"10.1128\/AAC.01383-18","article-title":"Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment","volume":"62","author":"Alfarisi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081609320830000_ciae329-B14","doi-asserted-by":"crossref","first-page":"1900373","DOI":"10.1183\/13993003.00373-2019","article-title":"Reduced moxifloxacin exposure in patients with tuberculosis and diabetes","volume":"54","author":"Dekkers","year":"2019","journal-title":"Euro Respir J"},{"key":"2024081609320830000_ciae329-B15","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"2024081609320830000_ciae329-B16","doi-asserted-by":"crossref","first-page":"2101925","DOI":"10.1183\/13993003.01925-2021","article-title":"Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China","volume":"59","author":"Zheng","year":"2022","journal-title":"Eur Respir J"},{"key":"2024081609320830000_ciae329-B17","doi-asserted-by":"crossref","first-page":"e3520","DOI":"10.1093\/cid\/ciaa1569","article-title":"Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response","volume":"73","author":"Zheng","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024081609320830000_ciae329-B18","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/507543","article-title":"Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes","volume":"43","author":"Nijland","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2024081609320830000_ciae329-B19","author":"World Health Organization"},{"key":"2024081609320830000_ciae329-B20","author":"Chinese Diabetes Society, National Office for Primary Diabetes Care"},{"key":"2024081609320830000_ciae329-B21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"2024081609320830000_ciae329-B22","doi-asserted-by":"crossref","first-page":"e0170022","DOI":"10.1128\/aac.01700-22","article-title":"Population pharmacokinetics and dose evaluation of cycloserine among patients with multidrug-resistant tuberculosis under standardized treatment regimens","volume":"67","author":"Zhu","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081609320830000_ciae329-B23","author":"World Health Organization"},{"key":"2024081609320830000_ciae329-B24","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3109\/00365548.2013.826876","article-title":"TBscore II: refining and validating a simple clinical score for treatment monitoring of patients with pulmonary tuberculosis","volume":"45","author":"Rudolf","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"2024081609320830000_ciae329-B25","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.2337\/dc23-S006","article-title":"6. Glycemic targets: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2024081609320830000_ciae329-B26","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1128\/AAC.01345-13","article-title":"Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus","volume":"57","author":"Babalik","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081609320830000_ciae329-B27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF03261926","article-title":"Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs","volume":"51","author":"Dostalek","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"2024081609320830000_ciae329-B28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1086\/519841","article-title":"The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis","volume":"45","author":"Alisjahbana","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024081609320830000_ciae329-B29","doi-asserted-by":"crossref","first-page":"e0186697","DOI":"10.1371\/journal.pone.0186697","article-title":"Effect of glycemic control and type of diabetes treatment on unsuccessful TB treatment outcomes among people with TB-diabetes: a systematic review","volume":"12","author":"Shewade","year":"2017","journal-title":"PLoS One"},{"key":"2024081609320830000_ciae329-B30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1186\/s12879-020-05473-x","article-title":"Slow radiological improvement and persistent low-grade inflammation after chemotherapy in tuberculosis patients with type 2 diabetes","volume":"20","author":"Mily","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2024081609320830000_ciae329-B31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/cid\/ciaa751","article-title":"Impact of intermediate hyperglycemia and diabetes on immune dysfunction in tuberculosis","volume":"72","author":"Eckold","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024081609320830000_ciae329-B32","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"2024081609320830000_ciae329-B33","author":"World Health Organization"},{"key":"2024081609320830000_ciae329-B34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-021-00997-0","article-title":"Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs","volume":"60","author":"Sturkenboom","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2024081609320830000_ciae329-B35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024081609320830000_ciae329-B36","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"New Engl J Med"},{"key":"2024081609320830000_ciae329-B37","doi-asserted-by":"crossref","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae329\/58540067\/ciae329.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/2\/524\/58831772\/ciae329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/2\/524\/58831772\/ciae329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T05:33:13Z","timestamp":1723786393000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/79\/2\/524\/7697997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6,24]]},"published-print":{"date-parts":[[2024,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae329","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8,15]]},"published":{"date-parts":[[2024,6,24]]}}}